Last price paid | 0.34 | |
Change | +3.03% [ +0.01 ] | |
Last traded volume | n.a. Unit | |
Cumulative volume | n.a. Unit | |
Date/time | 16.07.2024 17:20 |
Fixing | n.a. |
Settlement date | 12.03.2024 |
Last trading | n.a. |
Final fixing | n.a. |
Currency redemption | CHF |
Perf. since issue | -9.38% |
Year to date (YTD) | n.a. |
1 month | +21.43% |
3 months | -43.33% |
1 year | n.a. |
3 years | n.a. |
Issue price | 0.48 |
Underlying price on issue | 915.80 |
Premium | 0.01% |
Premium p.a. | n.a. |
Leverage | n.a. |
Implied volatility | n.a. |
ISIN | CH1305144078 |
Symbol | INOQ7Z |
Security | 130514407 |
Exchange | SIX Structured Products |
Currency | CHF |
Expiry | n.a. |
Underlying | Novo Nordisk -B-, DK0062498333 |
Underlying ISIN | DK0062498333 |
Funding level | 1090.825500 |
Stop-loss level | 1047.473200 |
Distance to stop-loss level | 12.17% |
Long/Short type | Short |
Subscription ratio | 50.00 |
Issuer | Zürcher Kantonalbank |
Exercise type | n.a. |
Minimum execution | n.a. |
Value day | 08.03.2024 |
Premium | 1.07% |
Premium p.a. | n.a. |
Leverage | 5.59 |
Moneyness | in-the-money |
Leverage | n.a. |
Delta | n.a. |
Intrinsic value | 157.025500 |
Break-even | n.a. |
SSPA value at risk | n.a. |
SSPA risk rating | n.a. |
SSPA derivative category | Leverage |
SSPA code | Mini future (2210) |
Name | Price |
---|---|
ROCHE GS | 274.60 |
Lonza Group | 514.40 |
SWISSCOM N | 526.50 |
Sika AG | 262.20 |
NOVARTIS N | 98.65 |
Name | Price |
---|---|
Alcon AG | 78.54 |
LOGITECH INT. | 80.54 |
Compagnie Financi... | 135.85 |
SONOVA HLDG N | 266.30 |
Givaudan | 4'217.00 |